Orexigen Therapeutics (OREX) Reports In-Line Q1 Loss of 14c/Share

Orexigen Therapeutics (NASDAQ: OREX) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $4.36 million versus the consensus estimate of $7.28 million.

As of March 31, 2015, Orexigen had $75.1 million in cash and cash equivalents and an additional $113.5 million in marketable securities, for a total of $188.6 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c